{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:43:54Z","timestamp":1789778634729,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn\u2019s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn\u2019s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4\u2009\u00b1\u200912.6\u00a0\u03bcg\/ml at week 0, 15.5\u2009\u00b1\u20097.7\u00a0\u03bcg\/ml at week 12, 15.7\u2009\u00b1\u20099.6\u00a0\u03bcg\/ml at week 24, and 14.5\u2009\u00b1\u20096.8\u00a0\u03bcg\/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.391 at week 0,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.563 at week 24,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.697 at week 52; MES:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.534 at week 0,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.429 at week 12,\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.636, CRP:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.402, fCal:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.435; MES: LRG:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.568, CRP: 0.389, fCal:\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.426).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-021-01793-0","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T17:18:31Z","timestamp":1620062311000},"page":"560-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Torisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shiotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinta","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1793_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769\u201378.","journal-title":"Lancet"},{"key":"1793_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","volume":"54","author":"Y Murakami","year":"2019","unstructured":"Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019;54:1070\u20137.","journal-title":"J Gastroenterol"},{"key":"1793_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, et al. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53:585\u201390.","journal-title":"J Gastroenterol"},{"key":"1793_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"1793_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u201370.","journal-title":"J Crohns Colitis"},{"key":"1793_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426\u201331.","journal-title":"Gut"},{"key":"1793_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/MIB.0000000000000341","volume":"21","author":"JD Falvey","year":"2015","unstructured":"Falvey JD, Hoskin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjy184","volume":"13","author":"A Walsh","year":"2019","unstructured":"Walsh A, Kormilitzin A, Hinds C, et al. Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis-a prospective analysis. J Crohns Colitis. 2019;13:424\u201330.","journal-title":"J Crohns Colitis"},{"key":"1793_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.118919","volume":"69","author":"S Serada","year":"2010","unstructured":"Serada S, Fujimoto M, Ogata A, et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010;69:770\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1793_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1515\/bchm2.1977.358.1.639","volume":"358","author":"H Haupt","year":"1977","unstructured":"Haupt H. Baudner S [Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum (author\u2019s transl)]. Hoppe Seylers Z Physiol Chem. 1977;358:639\u201346.","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"1793_CR11","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/ibd.22936","volume":"18","author":"S Serada","year":"2012","unstructured":"Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18:2169\u201379.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","volume":"11","author":"S Shinzaki","year":"2017","unstructured":"Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis. 2017;11:84\u201391.","journal-title":"J Crohns Colitis"},{"key":"1793_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","volume":"53","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305\u201353.","journal-title":"J Gastroenterol"},{"key":"1793_CR14","first-page":"505","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. GastrointestEndosc. 2004;60:505\u201312.","journal-title":"GastrointestEndosc"},{"key":"1793_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"1793_CR16","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","volume":"65","author":"L Vuitton","year":"2016","unstructured":"Vuitton L, Marteau P, Sandborn WJ, et al. IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials. Gut. 2016;65:1447\u201355.","journal-title":"Gut"},{"key":"1793_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","volume":"132","author":"G D'Haens","year":"2007","unstructured":"D\u2019Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763\u201386.","journal-title":"Gastroenterology"},{"key":"1793_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut"},{"key":"1793_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/ecco-jcc\/jjx049","volume":"11","author":"C Smids","year":"2017","unstructured":"Smids C, Horjus T, Horje CS, Nierkens S, et al. Candidate serum markers in early crohn\u2019sdisease:predictors of disease course. J Crohns Colitis. 2017;11:1090\u2013100.","journal-title":"J Crohns Colitis"},{"key":"1793_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MIB.0b013e318280eade","volume":"19","author":"S Shinzaki","year":"2013","unstructured":"Shinzaki S, Kuroki E, Iijima H, et al. Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn\u2019s disease. Inflamm Bowel Dis. 2013;19:321\u201331.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR21","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2018","unstructured":"Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779\u201389.","journal-title":"Lancet"},{"issue":"1275\u20131285","key":"1793_CR22","first-page":"e2","volume":"149","author":"BE Sands","year":"2015","unstructured":"Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(1275\u20131285):e2.","journal-title":"Gastroenterology"},{"key":"1793_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al. Fecalcalprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR24","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/jgh.14310","volume":"33","author":"F Iwamoto","year":"2018","unstructured":"Iwamoto F, Matsuoka K, Motobayashi M, et al. Prediction of disease activity of Crohn\u2019s disease through fecalcalprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol. 2018;33:1984\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1793_CR25","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1097\/MIB.0000000000001202","volume":"23","author":"K Kawashima","year":"2017","unstructured":"Kawashima K, Ishihara S, Yuki T, et al. Fecalcalprotectin more accurately predicts endoscopic remission of crohn\u2019s disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis. 2017;23:2027\u201334.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR26","first-page":"56","volume":"15","author":"T Arai","year":"2017","unstructured":"Arai T, Takeuchi K, Miyamura M, et al. Level of fecalcalprotectin correlates with severity of small bowel crohn\u2019s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. ClinGastroenterolHepatol. 2017;15:56\u201362.","journal-title":"ClinGastroenterolHepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01793-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01793-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01793-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:11:33Z","timestamp":1621491093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01793-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01793-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KM reports personal fees from EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Abbvie Inc., Mochida Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Alfressa Pharma Corporation, JIMRO Co., Ltd.; research grant from Janssen Pharmaceutical K.K., outside the submitted work. HT reports personal fees from JIMRO Co., Ltd., AbbVie GK, EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., outside the submitted work. SK reports personal fees from Abbvie Inc., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K.; grants from Abbvie Inc., EA Pharma Co., Ltd., outside the submitted work. TTo reports grants from Mitsubishi Tanabe Pharma Corporation, Abbvie Inc., EA Pharma Co., Ltd., outside the submitted work. KW reports grants and personal fees from AbbVie Japan Co., Ltd., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Pfizer Japan Inc., Kissei Pharmaceutical Co., Ltd., outside the submitted work; endowed chair from AbbVie Japan Co., Ltd., EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., JIMRO Co Ltd., Mochida Pharmaceutical Co., Ltd., Asahi Kasei Medical Co., Ltd., Otsuka Pharma Factory Inc. SNa reports personal fees and endowed chair from Mitsubishi Tanabe Pharma Corporation, Abbvie Inc., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Kyorin Holdings Inc., JIMRO Co Ltd., Zeria Pharmaceutical Co., Ltd.; research grants from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., endowed chair from Otsuka Pharma Factory Inc., outside the submitted work. YN reports personal fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., outside the submitted work. TKo reports personal fees from Alfresa Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Janssen, Abbvie GK, Pfizer; grants from Abbvie GK, EA Pharma, Otsuka Holdings, ZERIA, EA Pharma, Nippon Kayaku, JIMRO, outside the submitted work. AK reports personal fees from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichisankyo Co., Ltd.; research grants from Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., AstraZeneca K. K., Daiichisankyo Co., Ltd., outside the submitted work. FH reports personal fees from Abbvie GK, EA Pharma Co., Ltd, Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd., Takdeda Pharmaceutical Co., Ltd and Mitsubishi Tanabe Pharma, outside the submitted work. SH reports personal fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, outside the submitted work. WM reports personal fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Gilead Sciences, Inc., EA Pharma Co., Ltd.; research grants from Alfresa Pharma Corporation.; scholarship grants from Abbvie GK., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mochida Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., Alfresa Pharma Corporation., outside the submitted work. MM reports personal fees from Janssen Pharmaceutical K.K. and grants from Nippon Kayaku Co., Ltd., outside the submitted work. SNi is an employee of Eisai Co. Ltd. TTa reports personal fees from Abbvie GK, and grants from Abbvie GK, EA Pharma Co., Ltd, Eisai Co., Ltd., outside the submitted work. TN reports grants from Sekisui Medical Co., Ltd., outside the submitted work. TKa reports research grants from Miyarisan Pharmaceutical Co., Ltd., Ezaki Glico Co., Ltd.; scholarship grants from Abbvie GK, Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichisankyo Co., Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd, JIMRO Co., Ltd., outside the submitted work. TM reports personal fees from Abbvie GK, EA Pharma Co., Ltd, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co. Ltd.; grants from Mitsubishi Tanabe Pharma, Nippon Kayaku Co., Ltd., outside the submitted work. The other authors have no conflict of interest to disclose. Kochi University is a Patent holder for LRG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the latest version of the declaration of Helsinki. This study was approved by the Institutional Review Board or the Ethical Committee at each institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}